Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. - Wikidata - wikimedia - TriplyDB

Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.

Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.

http://www.wikidata.org/entity/Q46058203

about

Exercise for cancer cachexia in adults Exercise for cancer cachexia in adults Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)Towards curative therapy in gastric cancer: Faraway, so close!Interactions between muscle stem cells, mesenchymal-derived cells and immune cells in muscle homeostasis, regeneration and disease Muscle dysfunction in cancer patients The evaluation of body composition: a useful tool for clinical practice Lean tissue imaging: a new era for nutritional assessment and intervention.Body composition changes in females treated for breast cancer: a review of the evidence Gaps in nutritional research among older adults with cancer The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients Cancer cachexia: impact, mechanisms and emerging treatments Lower Pectoralis Muscle Area Is Associated with a Worse Overall Survival in Non-Small Cell Lung Cancer Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma Lean body mass: the development and validation of prediction equations in healthy adults Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer Inflammation based regulation of cancer cachexia Herbal medicines for cancer cachexia: protocol for a systematic review.Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.Panoramic ultrasound: a novel and valid tool for monitoring change in muscle mass Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia.Progressive resistance training and cancer testis (PROTRACT) - efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial.Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service Understanding cancer-induced cachexia: imaging the flame and its fuel.Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer.Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis.Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer The diversity of nutritional status in cancer: new insights Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.The effect of individualized nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: a randomized controlled trial protocol Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.Risk factors, complications and survival after upper abdominal surgery: a prospective cohort study.Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer cachexia.Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.

P2860

Q24187827-C28256E0-6B64-41D0-8C32-D986811B721A Q24197733-8A39A2C9-BCF7-46E6-8742-0F72A83136AB Q26747940-41B1B8E5-DD14-431E-8D44-7C43E01E45F3 Q26778029-CA2BC90B-E4F3-4C0B-AC38-A0580B002D1B Q26800192-6BB260AE-CBF2-4F80-B932-0C0793B95BE8 Q26822365-54433C35-9F06-4EB1-B19F-C74F5DEDDB84 Q26825173-7F69B488-5F36-43EA-84CA-223E74AB16B3 Q26865480-71DD3634-2553-4EC9-9F26-924FE949D773 Q27004662-4A01EEB8-0241-4838-B3A6-85CC51F4AFA6 Q28067552-F91F2E5F-5326-4062-B5FD-01F7D227843E Q28081125-90107373-BCA8-4932-B21C-9A6510199B1B Q28364947-7FAB675C-6FA4-480B-B5E5-B7EF7D3C9B94 Q28384479-E92BB55D-09B2-478B-B371-60FA6664DEFA Q28394473-B777E50F-6B52-4C97-A9FC-335A2EA6B9BE Q28545175-9F72A5DA-CE49-4368-A3B9-9947EA7B48FB Q28729059-59924255-1AD4-4FA8-9933-1D46059372A4 Q31150922-CD73203A-C11C-4386-A18B-4243B338572C Q33349016-CA1442FF-B656-401A-B950-0857E811E0F8 Q33400294-FB54BF47-8ED1-498C-B642-DE8CA31153AD Q33403870-A2C9B753-8C61-4717-883A-8656419A6EA5 Q33589369-38071CF3-625F-4178-9F46-B08CA7DFC2B1 Q33615916-97466F93-6F74-4CD1-A3AA-3E5DE700B486 Q33744800-98EFCBF7-AFC4-46F4-871C-3428DE578AC7 Q33765436-50A0D5AD-1FC4-46E2-AEE3-2D9340EA1391 Q33813569-1D7D7032-3946-42C7-92B5-C3506E1D7091 Q33880985-C5325C21-4E55-4C2F-8E70-39380D0EC282 Q33977589-A9FF6347-8186-4BEF-A003-FBFE608E1496 Q34123648-6E2EB69F-4325-4B3E-9B7D-5468D3DCAA09 Q34138093-9D04703C-4F8A-47DE-A298-36E129B649B4 Q34228955-A84DF7DC-1450-4815-8C9C-DF5E668AA2B5 Q35097594-7BCDA308-A04A-4479-8AD8-B744945E1678 Q35166583-C6AC32E2-52CA-4081-B87E-16641DC600D2 Q35584083-379B04CA-EDC6-473F-9582-11D3D9899BA2 Q35584120-143EE319-BA7B-44D1-9721-04089C277AF6 Q35605586-4F78B37F-0714-45C0-B79C-D89A0F52F6BC Q35662253-E7F73D8F-415D-4774-BCC6-DF775ECCEA5C Q35674557-AE8D455B-8667-495E-B893-E1C0588B4AE1 Q35684454-3A1AEFEC-EDEC-455D-80F0-8EA747713DC9 Q35690207-F4232A73-6443-4232-8B32-CDE7C3AEC438 Q35708619-BDD8EF99-7992-4CA5-8B2B-24E185171050

P2860

Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.

http://www.wikidata.org/entity/Q46058203

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Sarcopenia as a determinant of ...... eiving capecitabine treatment.

@en

Sarcopenia as a determinant of ...... eiving capecitabine treatment.

@nl

type

label

Sarcopenia as a determinant of ...... eiving capecitabine treatment.

@en

Sarcopenia as a determinant of ...... eiving capecitabine treatment.

@nl

prefLabel

Sarcopenia as a determinant of ...... eiving capecitabine treatment.

@en

Sarcopenia as a determinant of ...... eiving capecitabine treatment.

@nl

P1433

Q46058203-B97B7E1C-AE44-4795-B73E-CE5E59BBDDFA

P1476

Q46058203-48472C90-60A2-42BA-AB4F-EB734E2318B7

P2093

Q46058203-1DB4C0CF-5475-4534-9A1F-8B88298FA46E

Q46058203-25303F12-6173-42D7-A3BA-D9A22B72F449

Q46058203-357D5C5F-F105-45A7-81EC-4F18B99A71CA

Q46058203-5911BD9B-594F-49B6-BCA9-9480E712FA35

Q46058203-7CBB73DE-2ACC-4FC4-BEA2-937CDE895AB5

Q46058203-80D99F86-7392-42C7-94B3-30494EFE2247

Q46058203-BE5259ED-11F5-4610-B75F-514CAF995B83

Q46058203-DA6477B2-FFD4-4212-9613-31CBE71962A9

Q46058203-EE68C78F-2BAA-40CB-8A8D-24CC41CDBEE4

P304

Q46058203-6361C57F-0814-423F-BF42-1DEA61885BDA

P31

Q46058203-FCC9A7A3-2DFC-40A5-9ED0-36B4DD67B1CB

P356

Q46058203-4085BC57-F28A-4E95-8068-3CD69663289E

P407

Q46058203-A919F3E0-0CC5-49E6-88BE-85EE322B7E03

P433

Q46058203-3C1A35B4-A161-4963-B770-CCF93A087C07

P478

Q46058203-86D6C346-F374-4683-A64E-FAACDDC85851

P50

Q46058203-04C3386B-5E9F-47C9-A5E7-2490DB1D850E

P577

Q46058203-ACAF7464-7F6B-455D-B860-71996D2AA623

P698

Q46058203-6A60D86C-1E03-425C-B2A7-A637EBEAAA03

P921

Q46058203-04CD4D25-B670-4074-AB66-59EE52F74263

Q46058203-47F6B2A2-C892-4175-85E8-07E79250DD6D

P356

1078-0432.CCR-08-2242

P1433

Clinical Cancer Research

P1476

Sarcopenia as a determinant of ...... eiving capecitabine treatment.

@en

P2093

Carla M M Prado

http://www.w3.org/2001/XMLSchema#string

Edith Pituskin

http://www.w3.org/2001/XMLSchema#string

John R Mackey

http://www.w3.org/2001/XMLSchema#string

Katia Tonkin

http://www.w3.org/2001/XMLSchema#string

Linda J McCargar

http://www.w3.org/2001/XMLSchema#string

Marina Mourtzakis

http://www.w3.org/2001/XMLSchema#string

Michael B Sawyer

http://www.w3.org/2001/XMLSchema#string

Sheryl Koski

http://www.w3.org/2001/XMLSchema#string

Tony Reiman

http://www.w3.org/2001/XMLSchema#string

P304

2920-2926

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-2242

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Vickie E. Baracos

P577

2009-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19351764

http://www.w3.org/2001/XMLSchema#string

P921